抗人鼻病毒药物的研究进展  

Current development of agents against human rhinoviruses

作　　者：田君[1] 井申荣[1] 曾韦锟[1] 

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650224

出　　处：《云南大学学报（自然科学版）》2009年第S1期502-504,共3页Journal of Yunnan University(Natural Sciences Edition)

基　　金：云南省应用基础研究资助项目(2007C032M);国家自然科学基金资助项目(30872398);国家"863"计划重大项目资助(2006AA02A227)

摘　　要：人鼻病毒(Human rhinovirus,HRV)是引起人呼吸道感染的主要病原体,可导致哮喘加重甚至肺部纤维化等严重的呼吸道疾病.由于这是一种血清型分类最多的病毒,多达100多种,如何获得广谱的抗病毒药物成为研究的重点.随着病毒学的不断完善,对病毒结构的深入了解,针对人鼻病毒的药物不断地被研发,如Win系列化合物,Biota系列化合物等,不少已经进入Ⅳ期临床.就近几年人鼻病毒的研究进展做一综述.Human rhinoviruses(HRV) are the major cause of respiratory tract infection,inducing many severe diseases such as asthma exacerbation even fibrosis of the lung.Because of HRV,comprising over 100 different serotypes,how to gain broad-spectrum antiviral drugs becomes the key of research.Following the development of virology and the comprehension of the construction of HRV,anti-HRV-drugs are exploited in progression,for exemple,serial of Win and Biota chemical compound etc.And many of them are put into phase Ⅳ clinical experiment.This review presented the current development of human rhinoviruses.

关 键 词：人鼻病毒 抗病毒药物 研究进展 

分 类 号：R512.99[医药卫生—内科学]